Targeting Epilepsy Ictogenesis Process Through Pannexin-1 Modulation
Epilepsy, affecting about 1% of the population, comprises a group of neurological disorders characterized by the periodic occurrence of seizures, which disrupt normal brain function. Despite treatment with current antiepileptic dr...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PANNEXIN
Pannexin 1 – a novel target for pediatric orphan epilepsy
4M€
Cerrado
RTI2018-098768-B-I00
PATOFISIOLOGIA DE LOS COMPLEJOS NMADR-BK EN EL CEREBRO
230K€
Cerrado
WWOXAID
A Promising Treatment of WWOX Associated Neurological Disord...
150K€
Cerrado
EpiPrevent
The P2X7 receptor as treatment target for traumatic brain in...
216K€
Cerrado
BFU2015-66490-R
MECANISMOS MOLECULARES SUBYACENTES AL PAPEL NEUROPROTECTOR Y...
157K€
Cerrado
PID2020-118127RB-I00
SINTESIS DE COMPUESTOS CON MECANISMOS INNOVADORES CONTRA ENF...
272K€
Cerrado
Información proyecto PanThera
Duración del proyecto: 22 meses
Fecha Inicio: 2022-05-31
Fecha Fin: 2024-03-31
Líder del proyecto
COLLEGE DE FRANCE
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
150K€
Descripción del proyecto
Epilepsy, affecting about 1% of the population, comprises a group of neurological disorders characterized by the periodic occurrence of seizures, which disrupt normal brain function. Despite treatment with current antiepileptic drugs, one third of epileptic patients are pharmacoresistant and most patients suffer from side effects, making it crucial to develop novel therapies. Current drugs indeed target channels and receptors involved in normal brain function, not specific to the disease.
Our academic work has recently identified a novel and innovative target for epilepsy. Our project thus aims at bringing to the market a new generation of antiepileptic drugs specifically targeting the disease.